Skip to main content
SpringerLink
Log in

The vitamin D3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Exposure of MCF-7 breast tumor cells to the vitamin D3 analog, EB 1089 enhances the response to adriamycin. Clonogenic survival studies indicate that EB 1089 shifts the dose-response curve for sensitivity to adriamycin by approximately six-fold in p53 wild-type MCF-7 cells; comparative studies in MCF-7 cells with a temperature-sensitive dominant negative p53 mutation show less than a two-fold shift in adriamycin sensitivity in the presence of EB 1089. The combination of EB 1089 with adriamycin also promotes apoptotic cell death in the p53 wild-type MCF-7 cells but not in the MCF-7 cells expressing mutant p53. EB 1089 treatment blocks the increase in p21waf1/cip1 levels induced by adriamycin and interferes with induction of MAP kinase activity by ionizing radiation, effects which could be related to the capacity of EB 1089 to promote secretion of insulin-like growth factor binding protein. Taken together with our previous findings that EB 1089 enhances breast tumor cell sensitivity to ionizing radiation, there studies further support the concept that vitamin D3 analogs could have utility in combination with conventional chemotherapy and/or radiotherapy in the treatment of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Chapter © 2017

References

  1. Henderson IC, Canellos GP: Cancer of the breast: the past decade. N Engl J Med 302: 78-90, 1980

    Google Scholar 

  2. De Vita VT, Hellman S, Rosenberg SA, Cancer: Principle and Practice of Oncology. 5th ed. Lippincott-Raven, Philadelphia, 1997

    Google Scholar 

  3. Falzon M: The noncalcemic vitamin D analogues EB 1089 and 2-oxacalcitriol interact with vitamin D receptor and suppress parathyroid hormone-related gene expression. Mol Cell Endocrinol 127: 99-108, 1997

    Google Scholar 

  4. Yu J, Papvasiliou V, Rhim J, Goltzman D, Kremer R: Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia. Anticancer Drugs 6: 101-108, 1995

    Google Scholar 

  5. Vink-van-Wijngaarden T, Pols HA, Buurman CJ, van-den-Bemd GJ, Dorssers LC, Birkenhager JC, van-Leeuwen JP: Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res 54: 5711-5717, 1994

    Google Scholar 

  6. Cho YL, Christensen C, Saunders DE, Lawrence WD, Deppe M, Malviya VK, Malone JM: Combined effects of 1, 25 dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells. Cancer Res 51: 2848-2853, 1991

    Google Scholar 

  7. Light BW, Yu WD, McElwain MC, Russell DM, Trump DL, Johnson CS: Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res 57: 3759-3764, 1997

    Google Scholar 

  8. Ravid A, Rocker D, Machlenkin A, Rotem C, Hochman A, Kessler-Icekson G, Liberman UA, Koren R: 1, 25-dihyroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res 59: 862-867, 1999

    Google Scholar 

  9. Sundaram S, Gewirtz DA: The vitamin D3 analog EB 1089 enhances the response of human breast tumor cells to radiation. Rad Res 152: 479-486, 1999

    Google Scholar 

  10. Watson NC, Di YM, Orr MS, Fornari FA, Randolph JK, Magnet KJ, Jain PT, Gewirtz DA: The influence of ionizing radiation on proliferation, c-myc expression and the induction of apoptotic cell death in two breast tumor cell lines differing in p53 status. Int J Rad Biol 72: 547-559, 1997

    Google Scholar 

  11. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493-501, 1992

    Google Scholar 

  12. Reardon DB, Contessa JN, Mikkelsen RB, Valerie K, Amir C, Dent P, Schmidt-Ullrich RK: Dominant negative EGFRCD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. Oncogene 18: 4756-4766, 1999

    Google Scholar 

  13. Robert J, Illiadis A, Hoerni B, Cano J, Durand M, Lagarde C: Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. Eur J Cancer Clin Oncol 18: 739-745, 1982

    Google Scholar 

  14. Andres JL, Fan S, Turkel GJ, Wang J, Twu N, Yuan R, Lamszus K, Glodberg ID, Rosen EM: Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA damaging agents. Oncogene 16: 2229-2241, 1998

    Google Scholar 

  15. Lowe SW, Ruley HE, Jacks T, Housman DE: P53 dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993

    Google Scholar 

  16. Lowe SW, Bodis S, Remington L, Ruley HE, Fisher D, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266: 807-810, 1994

    Google Scholar 

  17. Fornari FA, Jarvis WD, Grant S, Orr MS, Randolph JK, White FKH, Gewirtz DA: Growth arrest and non-apoptotic cell death associate with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin. Biochem Pharmacol 51: 931-940, 1996

    Google Scholar 

  18. Fornari FA, Jarvis WD, Grant S, Orr MS, Randolph JK, White FKH, Mumaw VR, Lovings ET, Freeman RH, Gewirtz DA: Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin. Cell Growth Diff 5: 723-733, 1994

    Google Scholar 

  19. Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman JA, Wakeling AE, Walker PR, Sikorska M: Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 12: 3679-3684, 1993

    Google Scholar 

  20. Whitacre CM, Berger NA: Factors affecting topotecan induced programmed cell death: adhesion protects cells from apoptosis and impairs cleavage of poly(ADP-ribose-polymerase. Cancer Res 57: 2157-2163, 1997

    Google Scholar 

  21. Wosikowski K, Regis JT, Robey RW, Alvarez M, Buters JT, Gudas JM, Bates SE: Normal p53 status and function despite the development of drug resistance in human breast cancer cells. Cell Growth Diff 6: 139-151, 1995

    Google Scholar 

  22. Attardi LD, Lowe SW, Brugarolas J, Jacks T: Transcriptional activation by p53 but not induction of the p21 gene is essential for oncogene mediated apoptosis. EMBO J 15: 3693-3701, 1996

    Google Scholar 

  23. Gorospe M, Cirielli C, Wang X, Seth P, Capogrossi MC, Holbrook NJ: P21 waf1/cip1 protects against p53 mediated apoptosis of human melanoma cells. Oncogene 14: 929-935, 1997

    Google Scholar 

  24. Kagawa S, Fujiwara T, Hizuta A, Yasuda T, Zhang W-W, Roth JA, Tanaka N: p53 expression overcomes p21waf1/cip1 mediated G1 arrest and induces apoptosis in human cancer cells. Oncogene 15: 1903-1909, 1997

    Google Scholar 

  25. Park JS, Carter S, Reardon DB, Schmidt-Ullrich R, Dent P, Fisher PB: Roles for basal and stimulated p21 (Cip-1/Waf1/MDA6) expression and mitogen-activated protein kinase signaling in radiation-induced cell cycle checkpoint control in carcinoma cells. Mol Cell Biol 10: 4231-4246, 1999

    Google Scholar 

  26. Kivinen L, Tsubari M, Haapajarvi T, Datto MB, Wang XF, Laihi M: Ras induces p21 waf1/cip1 cyclin kinase inhibitor transcriptionally through SP1-binding sites. Oncogene 18: 6252-6261, 1999

    Google Scholar 

  27. Kivinen L, Laiho M: Ras and mitogen-activated protein kinase dependent and independent pathways in p21Cip1/Waf1 induction by fibroblast growth factor-2, platelet-derived growth factor and transforming growth factor. Cell Growth Diff 10: 621-628, 1999

    Google Scholar 

  28. Moffatt KA, Johannes WU, Miller GJ: 1 alpha 25-Dihydroxy vitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin Cancer Res 5: 695-703, 1999

    Google Scholar 

  29. Rocker D, Ravid A, Liberman UA, Garach-Jehoushua O, Koren R: 1, 25-Dihydroxyvitamin D3 potentiates the cytotoxic effect of TNF on human breast cancer cells. Mol Cell Endocrinol 106: 157-162, 1994

    Google Scholar 

  30. Koshizuka K, Koike M, Asou H, Cho SK, Stephen T, Rude RK, Binderup L, Uskokovic M, Koeffler HP: Combined effect of vitamin D3 analogs and paclitaxel on growth of MCF-7 breast cancer cells in vivo. Breast Cancer Res Treat 53: 113-120, 1999

    Google Scholar 

  31. Van Weelden K, Flanagan L, Binderup L, Tenniswood M, Welsh J: Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB 1089. Endocrinol 139: 2102-2110, 1998

    Google Scholar 

  32. Gulliford T, English J, Colston KW, Menday P, Moller S, Coombes RC: A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer 78: 6-13, 1998

    Google Scholar 

  33. Haq M, Kremer R, Goltzman D, Rabbani SA: A vitamin D analogue (EB 1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy associated hypercalcemia in vivo. J Clin Invest 91: 2416-2422, 1993

    Google Scholar 

  34. Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741, 1999

    Google Scholar 

  35. Lock RB, Strabinskiene L: Dual modes of cell death induced by etoposide in human epithelial tumor cells allow Bc1-2 to inhibit apoptosis without affecting clonogenic survival. Cancer Res 56: 4006-4012, 1996

    Google Scholar 

  36. Han JW, Dionne CA, Kedersha NL, Goldmacher VS: p53 status affects the rate of onset but not the overall extent of doxorubicin-induced cell death in rat-1 fibroblasts constitutively expressing c-myc. Cancer Res 57: 176-182, 1997

    Google Scholar 

  37. Janicke RU, Spregart ML, Wati MR, Porter AG: Caspase 3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273: 9357-9360, 1998

    Google Scholar 

  38. Zakeri Z, BurschW, Tenniswood M, Lockshin RA: Cell death: programmed, apoptosis, necrosis or other. Cell Death Diff 2: 87-96, 1995

    Google Scholar 

  39. Comparison of methods based on Annexin-V binding, DNA content or TUNEL for evaluating cell death in HL-60 and adherent MCF-7 cells. Cell Prolif 32: 25-37, 1999

  40. Toma S, Isnardi L, Raffo P, Riccardi L, Dastoli G, Apfel C, LeMotte P, Bollag W: RAR alpha antagonist RO-41-5253 inhibits proliferation and induces apoptosis in breast cancer cell lines. Int J cancer 78: 86-94, 1998

    Google Scholar 

  41. Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, Cho-Chung YS, Longo DL: Involvement of microtubules in the regulation of Bc1-2 phosphorylation and apoptosis through cyclic AMP dependent protein kinase. Mol Cell Biol 18: 3509-3517, 1998

    Google Scholar 

  42. Chen H, Tritton TR, Kenny N, Absher M, Chiu J-F: Tamoxifen induces TGF-Beta 1 activity and apoptosis of human MCF-7 breast cancer cells in vitro. J Cell Biochem 6: 9-17, 1996

    Google Scholar 

  43. Parrizas M, Saltiel AR, LeRoith D: Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 30 kinase and mitogen activated protein kinase pathways. J Biol Chem 272: 154-161, 1997

    Google Scholar 

  44. Kulik G, Klippel A, Weber MJ: Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3 kinase and Akt. Mol Cell Biol 17: 1595-1606, 1997

    Google Scholar 

  45. Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN, Hay N: The P13 kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev 11: 701-713, 1997

    Google Scholar 

  46. Martin JL, Baxter RC: Oncogenic ras causes resistance to the growth inhibitor insulin-like growth factor binding protein 3 (IGFBP-3) in breast cancer cells. J Biol Chem 274: 16407-16411, 1999

    Google Scholar 

  47. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell intrinsic death machinery. Cell 91: 231-234, 1997

    Google Scholar 

  48. Fang X, Yu S, Eder A, Mao M, Bast RC, Boyd D, Gills GB: Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen activated protein kinase pathway. Oncogene 18: 6635-6640, 1999

    Google Scholar 

  49. Colston KW, Perks CM, Xie SP, Holly JMP: Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3 J Mol Endocrinol 20: 157-162, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, Toxicology and Medicine, Virginia Commonwealth University, Medical College of Virginia, Richmond, VA

    S. Sundaram

  2. Department of Surgery, Dartmouth Medical School, Dartmouth College, Hanover, NH, USA

    S. Sundaram

  3. Department of Pharmacology, Toxicology and Medicine, Virginia Commonwealth University, Medical College of Virginia, Richmond, VA, USA

    M. Chaudhry, D. Reardon, M. Gupta & D.A. Gewirtz

  4. College of Pharmacy, University of Louisiana at Monroe, Monroe, LA, USA

    D. Reardon

Authors
  1. S. Sundaram
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Chaudhry
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Reardon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D.A. Gewirtz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sundaram, S., Chaudhry, M., Reardon, D. et al. The vitamin D3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells. Breast Cancer Res Treat 63, 1–10 (2000). https://doi.org/10.1023/A:1006420708806

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006420708806

Search

Navigation